|
|
|
|
US Medicare panel eyes ESA use in kidney patients
* Amgen, J&J likely may face pressure over kidney use * Medicare agency's panel to meet March 24 * Some analysts see sales of anemia drugs slipping (Adds Amgen comment) WASHINGTON (Reuters) - Closer government scrutiny of controversial anemia drugs made...
|
|
|
UPDATE 1-US Medicare panel eyes ESA use in kidney patients
* Amgen, J&J likely may face pressure over kidney use * Medicare agency's panel to meet March 24 * Some analysts see sales of anemia drugs slipping WASHINGTON, March 19 (Reuters) - Closer government scrutiny of controversial anemia drugs made by Amgen Inc ...
|
|
|
US Medicare panel eyes ESAs use in kidney patients
* Amgen, J&J likely may face pressure over kidney use * Medicare agency's panel to meet March 24 * Some analysts see sales of anemia drugs slipping WASHINGTON, March 19 (Reuters) - Closer government scrutiny of controversial anemia drugs made by Amgen Inc ...
|
|
|
US Medicare panel eyes ESAs use in kidney patients
* Amgen, J&J likely may face pressure over kidney use * Medicare agency's panel to meet March 24 * Some analysts see sales of anemia drugs slipping WASHINGTON, March 19 (Reuters) - Closer government scrutiny of controversial anemia drugs made by Amgen...
|
|
|
US Medicare panel eyes ESAs use in kidney patients
By Susan Heavey WASHINGTON, March 19 (Reuters) - Closer government scrutiny of controversial anemia drugs made by Amgen Inc and Johnson & Johnson is likely to reopen debate on how much the drugs should be used and could further depress sales.Next week,...
|
|
|
US Medicare panel eyes ESAs use in kidney patients
WASHINGTON, March 19 (Reuters) - Closer government scrutiny of controversial anemia drugs made by Amgen Inc and Johnson&Johnson is likely to reopen debate on how much the drugs should be used and could further depress sales.Next week, the Centers for...
|
|
|
Piper Jaffray Initiates Coverage on Amgen (AMGN) with a Neutral; Anemia Headwinds Remain
Piper Jaffray initiates coverage on Amgen Inc.(Nasdaq: AMGN) with a Neutral rating. Price target $62. Piper analyst says, "We expect presentation of denosumab Phase III prostate cancer data at the ASCO (June 4-8) to confirm the drug's blockbuster...
|
|
|
Fitch Affirms Amgen's IDR at 'A'; Rates New Issuance 'A'; Outlook...
Company: Amgen, Inc.(AMGN) Fitch Ratings has affirmed Amgen Inc. (Amgen) ratings as follows: Simultaneously, Fitch has assigned an 'A' rating to Amgen's proposed $1 billion debt issuance. Proceeds of the new debt are expected to be used for general...
|
|
|
S&P: Amgen Inc. Proposed $1 Billion Senior Unsecured Notes Due 2020, 2040, Rated 'A+'
-Standard & Poor's Ratings Services said today that it assigned its 'A+' issue-level rating to Thousand Oaks, Calif.-based Amgen Inc.'s proposed $1 billion senior unsecured notes, divided into two tranches, due 2020 and 2040.Proceeds from the notes...
|
|
|
A Cautious Look at Amgen's Denosumab
Amgen (AMGN) is global biotechnology company who sells pharmaceutical drugs, including Aranesp & Epogen (anemia), Enbrel (rheumatoid arthritis), and Neulasta & Neupogen (prevent infections in chemotherapy patients).Although there are...
|
|
|
A Cautious Look at Amgen's Denosumab
Amgen (AMGN) is global biotechnology company who sells pharmaceutical drugs, including Aranesp & Epogen (anemia), Enbrel (rheumatoid arthritis), and Neulasta & Neupogen (prevent infections in chemotherapy patients).Although there are concerns...
|
|
|
Fitch Affirms Amgen's IDR at 'A'; Rates New Issuance 'A'; Outlook Stable
CHICAGO--(BUSINESS WIRE)--Fitch Ratings has affirmed Amgen Inc.(Amgen) ratings as follows: --Issuer Default Rating (IDR) at 'A'; Simultaneously, Fitch has assigned an 'A' rating to Amgen's proposed $1 billion debt issuance. Proceeds of the new debt are...
|
|
|
Fitch Affirms Amgen's IDR at 'A'; Rates New Issuance 'A'; Outlook Stable
Fitch Ratings has affirmed Amgen Inc.(Amgen) ratings as follows: Simultaneously, Fitch has assigned an 'A' rating to Amgen's proposed $1 billion debt issuance. Proceeds of the new debt are expected to be used The Rating Outlook is Stable. The ratings...
|
|
|
NHS patients losing out as life-saving drugs are sold abroad
'Unscrupulous' pharmacies face closure threat over lucrative export trade in vital medicines Life-saving medicines meant only for sale in the UK are being sold for export at huge mark-ups, causing an acute shortage of drugs that is putting patients' lives at...
|
|
|
For some on dialysis, anemia drugs pose risks
TUESDAY, March 2 (HealthDay News) -- Powerful drugs that treat the anemia caused by kidney failure yield mixed results, depending on the severity of the anemia, a new study has shown.People on dialysis with severe anemia, according to the study, tend to live...
|
|
|
Erythropoiesis-Stimulating Agents (ESAs): Procrit, Epogen and Aranesp: Drug Safety Communication
FDA and Amgen notified healthcare professionals and patients that all ESAs must be used under a REMS risk management program.As part of the risk management program, a Medication Guide explaining the risks and benefits of ESAs must be provided to all patients...
|
|
|
For some on dialysis, anemia drugs pose risks
By Steven Reinberg HealthDay Reporter TUESDAY, March 2 (HealthDay News) -- Powerful drugs that treat the anemia caused by kidney failure yield mixed results, depending on the severity of the anemia, a new study has shown.People on dialysis with severe anemia...
|
|
|
For Some on Dialysis, Anemia Drugs Pose Risks
TUESDAY, March 2 (HealthDay News) -- Powerful drugs that treat the anemia caused by kidney failure yield mixed results, depending on the severity of the anemia, a new study has shown.People on dialysis with severe anemia, according to the study, tend to live...
|
|
|
For some on dialysis, anemia drugs pose risks
TUESDAY, March 2 (HealthDay News) -- Powerful drugs that treat the anemia caused by kidney failure yield mixed results, depending on the severity of the anemia, a new study has shown.People on dialysis with severe anemia, according to the study, tend to live...
|
|
|
Study of popular anemia drug supports new guidelines for its use in dialysis patients
A new study helps dispel mounting confusion over the safety of blockbuster anemia drugs - erythropoiesis-stimulating agents - for people with kidney disease requiring dialysis, as federal regulators prepare to decide whether to impose additional restrictions on...
|
|
|
For some on dialysis, anemia drugs pose risks
TUESDAY, March 2 (HealthDay News) -- Powerful drugs that treat the anemia caused by kidney failure yield mixed results, depending on the severity of the anemia, a new study has shown.People on dialysis with severe anemia, according to the study, tend to live...
|
|
|
Anemia drugs help end-stage anemic ki
London, March 03: Aggressive treatment with blockbuster anemia drugs may offer the best approach for kidney dialysis patients with severe anemia, US researchers said on Tuesday.But aggressive treatment only made things worse for patients in the final stages...
|
|
|
For Some on Dialysis, Anemia Drugs Pose Risks
TUESDAY, March 2 (HealthDay News) -- Powerful drugs that treat the anemia caused by kidney failure yield mixed results, depending on the severity of the anemia, a new study has shown.People on dialysis with severe anemia, according to the study, tend to live...
|
|
|
For some on dialysis, anemia drugs pose risks
TUESDAY, March 2 (HealthDay News) -- Powerful drugs that treat the anemia caused by kidney failure yield mixed results, depending on the severity of the anemia, a new study has shown.People on dialysis with severe anemia, according to the study, tend to live...
|
|
|
For some on dialysis, anemia drugs pose risks
TUESDAY, March 2 (HealthDay News) -- Powerful drugs that treat the anemia caused by kidney failure yield mixed results, depending on the severity of the anemia, a new study has shown.People on dialysis with severe anemia, according to the study, tend to live...
|
